Capecitabine (X) plus trastuzumab (H) as first-line treatment in patients (pts) with HER2-positive metastatic breast cancer (MBC): phase II trial results. L. Xu,S. Song,J. Zhu, R. Luo,L. Li, S. Jiao, H. Pan,M. Tao,Y. Su, D. LiuBREAST CANCER RESEARCH AND TREATMENT（2006）引用 0|浏览1暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
